Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

Not Applicable

• Conditions: Melanoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer

• Registration Number: NCT02105168
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2014-03-31
• Study First Submitted QC: 2014-04-02
• Study First Posted: 2014-04-07
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-09
• Last Update Posted: 2016-06-10
• Primary Completion: 2019-07
• Study Completion: 2019-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 2200

Inclusion Criteria

1. Cytological or histological diagnosis of SCLC, NSCLC or melanoma
2. Patients age >/= 18 years old
3. Indication of treatment using platinum salts for lung cancer except for patient with NSCLC treated by surgery for whom platinum salts is not indicated
4. If a biopsy is proposed, lesion lust be easily accessible
5. Signed informed consent

Exclusion Criteria

1. Patients unable to follow the protocol
2. Consent refusal

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Mutation rate on tumorous material	Assessed at the time of inclusion	Assessed at the time of inclusion using tumorous material used for diagnosis

Trial Locations

Locations (1)

Gustave Roussy Cancer Campus Grand Paris; 🇫🇷 Villejuif, Val de Marne, France